Form 8-K - Current report:
SEC Accession No. 0001551152-20-000004
Filing Date
2020-02-07
Accepted
2020-02-07 07:48:07
Documents
16
Period of Report
2020-02-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abbv-20191231x8k.htm   iXBRL 8-K 60349
2 EXHIBIT 99.1 abbv-20191231xexhibit9.htm EX-99.1 765607
8 logoabbviea05.gif GRAPHIC 2573
  Complete submission text file 0001551152-20-000004.txt   1094194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abbv-20200207.xsd EX-101.SCH 5648
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT abbv-20200207_cal.xml EX-101.CAL 697
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abbv-20200207_def.xml EX-101.DEF 18923
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abbv-20200207_lab.xml EX-101.LAB 41756
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abbv-20200207_pre.xml EX-101.PRE 20767
18 EXTRACTED XBRL INSTANCE DOCUMENT abbv-20191231x8k_htm.xml XML 12973
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 20584537
SIC: 2834 Pharmaceutical Preparations